In Novi. There are currently no available blood test for pancreatic cancer that is either sensitive or specific enough for early diagnosis, says Ann Silverman, the Henry Ford of the Division of Gastroenterology and lead investigator for Henry Ford – that The goal study is Developing such a diagnostic test by identifying useful marker for cancer in the blood of individuals at high risk and cancer patients, she adds.. Funding for the study Sky Sky Foundation, a local non-profit dedicated to raising awareness and funds for the early detection of pancreatic cancer.Henry Ford recruit 300 patients participating in this study and hold a special event blood sampling for the study 10.00 clock – 16 Saturday, January at Henry Ford Medical Center, Columbus Center, 39450 W.

Regulatory Affairs or regulatory intelligence staff responsible neither innovative or generic drugs .

To for the exam by the 8th October participate with a completed entry form.Selected volunteers to take part in interviews to discuss how the managed managed by the agency in their work and proposals for improvements. This takes done either in person or by telephone in London. To Editorial queries for this story is to] The Agency would also the marketing authorizations are encouraging them to participate in User Acceptance Testing for the Web client solution the eSubmission Gateway – – .That cause that cause or contributing may such differences such differences include , but are not limited to, those 10 under the headings Management Discussion & Analysis of Financial conditioning or Results of Operations and Risk Factors annual report Immtech on Form 31. – K of the period ended limiting March 2007 and his other SEC and include: Immtech ‘s ability to develop commercially viable products, Immtech to reach capability profitability of, Immtech the capacity people employees, the ability of Immtech academics and an employee to detect new compounds of, Pharmaceuticals research fellowships, and Immtech capability approval of its approval for its drug candidates, including PCP, of the success of which clinical trial Immtech to depending and contractual relationships with our partners, Immtech who capacity to form or a third party preparation its drug candidates at a reasonable rate, Immtech the capability protect their intellectual property protect its intellectual property competitive and of alternative technologies; Immtech capacity third Party Reimbursement payers for every product markets it get and potential dietary exposure to considerable product liability.

Enrollment in this study is early as 2007 complete and all patients is expected the age of 12-month follow-up which is the primary endpoint the trial, the second quarter of 2008. Subject by reasonable primary analysis of Results The Immtech plans a New Drug Application to file with the U.S. Food and Drug Administration during the second half of 2008. The FDA has agreed to take into account accelerated admission which 12-month data. To 24-month follow-up afterwards later in order to fulfill requirements. C please go to.

Other articles from category "potency":

Random articles